Embattled investment group Mayfair 101 is challenging a judge’s decision last month to slug it with a $30 million penalty for engaging in misleading and deceptive advertising.
A group of litigation funders will launch a major advertising campaign starting Monday against proposed legislation that puts a ceiling on the legal fees and commission they can recover from class actions.
The influence of an unvaccinated “iconic world tennis star” on the young and impressionable was not fanciful, the Full Federal Court has said in reasons for throwing out Novak Djokovic’s challenge to his deportation from Australia.
National Australia Bank has been served with a $78 million class action over the collapse of Walton Construction, three months after the case was stalled for funding complications.
A class action against franchise giant Retail Food Group wants to head off any challenge to its funding agreement with a court order that the financing arrangement is exempt from controversial regulations requiring group proceedings to be run as managed investment schemes.
The litigation funder behind a scam to defraud members of a class action over the collapse of Banksia Securities has entered liquidation, and the funder’s two surviving directors will be among potential targets of attempts to recover money to pay a $21.7 million court judgment.
The federal Attorney General’s Department has faced calls to reveal the constitutional heads of power behind the latest class action reform bill that aims to cap the amount of fees and commission lawyers and funders can earn.
Tennis star Novak Djokovic’s challenge to the Immigration Minister’s decision revoking his visa was unanimously dismissed Sunday, clearing the way for his removal and crushing his hopes for another Australian Open title.
If evidence were needed that courts are not rubber stamping class action settlements, the scrutiny of multi-million dollar agreements in 2021 is proof positive that judicial oversight of representative proceedings is robust.
Mylan’s Australia unit is appealing decisions by the tax office to refuse deductions on interest paid under loans taken out by the pharmaceutical giant to help fund the $1.2 billion acquisition of generic drug maker Alphapharm almost 15 years ago.